Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06660979 · ClinicalTrials.gov registry record · NA

Using Reinforcement Learning to Personalize Electronic Health Record Tools to Facilitate Deprescribing

A NA study of Aging, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT06660979: Recruiting NA study of Aging, sponsored by Brigham and Women's Hospital.

NCT06660979 is a NA study of Aging that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 70 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06660979, a NA study of Aging, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The overall goal of the proposed research is to refine and adapt and perform efficacy testing of a novel reinforcement learning-based approach to personalizing EHR-based tools for PCPs on deprescribing of high-risk medications for older adults. The trial will be conducted at Atrius Health, an integrated delivery network in Massachusetts, and will intervene upon primary care providers. The investigators will conduct a cluster randomized trial using reinforcement learning to adapt electronic health record (EHR) tools for deprescribing high-risk medications versus usual care. 70 PCPs will be randomized (i.e., 35 each to the reinforcement learning intervention and usual care \[no EHR tool\] in each arm) to the trial and follow them for approximately 30 weeks. The primary outcome will be discontinuation or ordering a dose taper for the high-risk medications for eligible patients by included primary care providers, using EHR data at Atrius. The primary hypothesis is that the personalized intervention using reinforcement learning will improve deprescribing compared with usual care.

Primary Outcome

Deprescribing will be assessed using routinely collected data from the EHR system for eligible patients flagged as in need of deprescribing. The deprescribing outcome will be a "reduction" in inappropriate prescribing, defined as either discontinuation of one the the medication classes of interest or ordering a dose taper.

Conditions Studied

Interventions

  • BEHAVIORAL Reinforcement learning

Study Locations (1)

Massachusetts

  • Atrius Health - Boston

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-08-11
Est. Completion 2026-05-31
Phase NA
Brigham and Women's Hospital

937 total trials

What NCT06660979 shows while recruiting

NCT06660979 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 1 intervention - of which Reinforcement learning is the first listed.

NCT06660979 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06660979 about?

NCT06660979 is a clinical study titled "Using Reinforcement Learning to Personalize Electronic Health Record Tools to Facilitate Deprescribing". The overall goal of the proposed research is to refine and adapt and perform efficacy testing of a novel reinforcement learning-based approach to personalizing EHR-based tools for PCPs on deprescribing of high-risk medications for older adults. The trial will be conducted at Atrius Health, an integr...

What is the current status of trial NCT06660979?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-08-11. Estimated completion is 2026-05-31.

What conditions does trial NCT06660979 study?

This clinical trial studies the following conditions: Aging.

What interventions are being tested in trial NCT06660979?

The interventions under investigation include: Reinforcement learning (BEHAVIORAL).

Who is sponsoring clinical trial NCT06660979?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06660979 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06660979's enrollment target sits among peer trials

70 125th of 262 higher than 136 of 262 other Aging trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06660979, the US trial registry maintained by the National Library of Medicine. NCT06660979 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.